268 related articles for article (PubMed ID: 33035097)
1. Sacral neuromodulation system for treating refractory overactive bladder.
Phillips A
Br J Nurs; 2020 Oct; 29(18):S30-S37. PubMed ID: 33035097
[TBL] [Abstract][Full Text] [Related]
2. Axonics Sacral Neuromodulation System for Treating Refractory Overactive Bladder: A NICE Medical Technologies Guidance.
Poole RL; Dale M; Morgan H; Oladapo T; Brookfield R; Morris R
Appl Health Econ Health Policy; 2022 May; 20(3):305-313. PubMed ID: 34964090
[TBL] [Abstract][Full Text] [Related]
3. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
[TBL] [Abstract][Full Text] [Related]
4. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Perrouin-Verbe MA; Elneil S
Neurourol Urodyn; 2020 Apr; 39(4):1108-1114. PubMed ID: 32243625
[TBL] [Abstract][Full Text] [Related]
5. Three month clinical results with a rechargeable sacral neuromodulation system for the treatment of overactive bladder.
Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe M; Elneil S
Neurourol Urodyn; 2018 Feb; 37(S2):S9-S16. PubMed ID: 29315785
[TBL] [Abstract][Full Text] [Related]
6. The novel Axonics® rechargeable sacral neuromodulation system: Procedural and technical impressions from an initial North American experience.
Elterman DS
Neurourol Urodyn; 2018 Feb; 37(S2):S1-S8. PubMed ID: 29336078
[TBL] [Abstract][Full Text] [Related]
7. Review of the rechargeable sacral neuromodulation system to treat refractory overactive bladder.
Albabtain M; Chughtai B; Cho A; Elterman D
Ther Deliv; 2021 May; 12(5):353-362. PubMed ID: 33821666
[TBL] [Abstract][Full Text] [Related]
8. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
Tilborghs S; De Wachter S
Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Urinary Urgency Incontinence Using a Rechargeable SNM System: 6-Month Results of the ARTISAN-SNM Study.
McCrery R; Lane F; Benson K; Taylor C; Padron O; Blok B; De Wachter S; Pezzella A; Gruenenfelder J; Pakzad M; Perrouin-Verbe MA; Le Normand L; Van Kerrebroeck P; Mangel J; Peters K; Kennelly M; Shapiro A; Lee U; Comiter C; Mueller M; Goldman HB
J Urol; 2020 Jan; 203(1):185-192. PubMed ID: 31347955
[TBL] [Abstract][Full Text] [Related]
10. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
Parnell BA; Howard JF; Geller EJ
Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
[TBL] [Abstract][Full Text] [Related]
11. [Sacral neuromodulation for refractory overactive bladder].
van Ophoven A
Urologe A; 2018 Nov; 57(11):1375-1388. PubMed ID: 30310935
[TBL] [Abstract][Full Text] [Related]
12. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
13. Cost profiles and budget impact of rechargeable versus non-rechargeable sacral neuromodulation devices in the treatment of overactive bladder syndrome.
Noblett KL; Dmochowski RR; Vasavada SP; Garner AM; Liu S; Pietzsch JB
Neurourol Urodyn; 2017 Mar; 36(3):727-733. PubMed ID: 27062384
[TBL] [Abstract][Full Text] [Related]
14. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
Girtner F; Burger M; Mayr R
Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
[TBL] [Abstract][Full Text] [Related]
15. An overview of sacral neuromodulation: a treatment for patients with symptoms of lower urinary tract dysfunction.
Fletcher N
Br J Nurs; 2020 Aug; 29(15):848-856. PubMed ID: 32790556
[TBL] [Abstract][Full Text] [Related]
16. Sacral neuromodulation: Rechargeable versus non-rechargeable device. What would the patient preferences be in France?
Gamé X; Ruffion A; Cornu JN; Phé V; Peyronnet B; Perrouin-Verbe MA; Aublant C; Adé A; Chartier-Kastler E
Prog Urol; 2022 Sep; 32(10):672-680. PubMed ID: 35752523
[TBL] [Abstract][Full Text] [Related]
17. Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study.
Kaaki B; Gupta D
PLoS One; 2020; 15(7):e0235961. PubMed ID: 32645082
[TBL] [Abstract][Full Text] [Related]
18. The role of neuromodulation in patients with neurogenic overactive bladder.
Lay AH; Das AK
Curr Urol Rep; 2012 Oct; 13(5):343-7. PubMed ID: 22865208
[TBL] [Abstract][Full Text] [Related]
19. Refractory overactive bladder after urethrolysis for bladder outlet obstruction: management with sacral neuromodulation.
Starkman JS; Duffy JW; Wolter CE; Kaufman MR; Scarpero HM; Dmochowski RR
Int Urogynecol J Pelvic Floor Dysfunct; 2008 Feb; 19(2):277-82. PubMed ID: 17671752
[TBL] [Abstract][Full Text] [Related]
20. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
